Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Wang, Zhenyao ^a,b   Hall, Monte D ^a,b   Rewers Felkins, Kathleen A ^a,c   Quinlin, Imelda S ^a,c   Wright, Stephen E ^a,b,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b WEST TEXAS A AND M UNIVERSITY   (United States)

^c Harrington Cancer Center   (United States)

Author keywords

Cytotoxic cells; Dendritic cells; Immunotherapy; Protection

Indexed keywords

INTERLEUKIN 4; MUCIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL ACTIVITY; CELL ASSAY; CELL KILLING; CELL STIMULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE FUNCTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; T LYMPHOCYTE ACTIVATION;

EID: 84886944778     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23335     Document Type: Article

References (48)

1. Carroll PR, DeVita VT Jr. Cancer of the Prostate. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2001:1418-79.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4; PMID:11357146; http://dx.doi.org/10.1038/35077246.
3. Wright SE, Kilinski L, Talib S, Lowe KE, Burnside JS, Wu JY, et al. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother 2000; 23:2-10; PMID:10687132; http://dx.doi.org/10.1097/00002371-200001000-00002.
4. Devine PL, McGuckin MA, Ramm LE, Ward BG, Pee D, Long S. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients. Cancer 1993; 72:2007-15; PMID:7689923; http://dx.doi.org/10.1002/1097-0142(19930915)72:6<2007::AIDCNCR2820720636>3.0.CO;2-U.
5. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988;263:12820-3; PMID:3417635.
6. Lan MS, Batra SK, Qi WN, Metzgar RS, Hollingsworth MA. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem 1990; 265:15294-9;PMID:2394722.
7. Guevara-Patiño JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 2006; 116:1382-90; PMID:16614758; http://dx.doi.org/10.1172/JCI25591.
8. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 1989; 86:7159-63; PMID:2674949; http://dx.doi.org/10.1073/pnas.86.18.7159.
9. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993; 151:3693-703; PMID:7690810.
10. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. [UNITEDSTATES]. Cancer Res 1991; 51:2908-16; PMID:1709586.
11. Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G, et al. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993;53:2457-9; PMID:8495404.
12. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588.
13. Ronchese F, Hausmann B, Le Gros G. Interferongamma-and interleukin-4-producing T cells can be primed on dendritic cells in vivo and do not require the presence of B cells. [GERMANY]. Eur J Immunol 1994; 24:1148-54; PMID:8181524; http://dx.doi.org/10.1002/eji.1830240521.
14. Albert SE, McKerlie C, Pester A, Edgell BJ, Carlyle J, Petric M, et al. Time-dependent induction of protective anti-influenza immune responses in human peripheral blood lymphocyte/SCID mice. J Immunol 1997; 159:1393-403; PMID:9233636.
15. Ifversen P, Mårtensson C, Danielsson L, Ingvar C, Carlsson R, Borrebaeck CA. Induction of primary antigen-specific immune reponses in SCID-hu-PBL by coupled T-B epitopes. Immunology 1995; 84:111-6; PMID:7534259.
16. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2:1122-8; PMID:8837611; http://dx.doi.org/10.1038/nm1096-1122.
17. Luykx-de Bakker SA, de Gruijl TD, Scheper RJ, Wagstaff J, Pinedo HM. Dendritic cells: a novel therapeutic modality. Ann Oncol 1999; 10:21-7; PMID:10076717; http://dx.doi.org/10.1023/A:1008349920664.
18. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999; 96:2233-8; PMID:10051624; http://dx.doi.org/10.1073/pnas.96.5.2233.
19. Ludewig B, Oehen S, Barchiesi F, Schwendener RA, Hengartner H, Zinkernagel RM. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J Immunol 1999; 163:1839-44; PMID:10438917.
20. Wright SE, Rewers-Felkins KA, Quinlin IS, Eldridge PW, Zorsky PE, Klug PP, et al. Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med 2002; 9:401-4; PMID:11891536.
21. Conti L, Gessani S. GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology 2008; 213:859-70; PMID:18926300; http://dx.doi.org/10.1016/j.imbio.2008.07.017.
22. Arpa L, Valledor AF, Lloberas J, Celada A. IL-4 blocks M-CSF-dependent macrophage proliferation by inducing p21Waf1 in a STAT6-dependent way. Eur J Immunol 2009; 39:514-26; PMID:19130475; http://dx.doi.org/10.1002/eji.200838283.
23. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992; 176:1091-8; PMID:1328464; http://dx.doi.org/10.1084/jem.176.4.1091.
24. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994; 180:1715-28; PMID:7525836; http://dx.doi.org/10.1084/jem.180.5.1715.
25. Boni A, Iezzi G, Degl'Innocenti E, Grioni M, Jachetti E, Camporeale A, et al. Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic T lymphocytes. Eur J Immunol 2006; 36:3157-66; PMID:17111344; http://dx.doi.org/10.1002/eji.200535597.
26. Wang J, Alvarez R, Roderiquez G, Guan E, Caldwell Q, Wang J, et al. CpG-independent synergistic induction of beta-chemokines and a dendritic cell phenotype by orthophosphorothioate oligodeoxynucleotides and granulocyte-macrophage colony-stimulating factor in elutriated human primary monocytes. J Immunol 2005; 174:6113-21; PMID:15879106.
27. Zou W, Borvak J, Marches F, Wei S, Galanaud P, Emilie D, et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol 2000; 165:4388-96; PMID:11035076.
28. Chakraborty NG, Sporn JR, Tortora AF, Kurtzman SH, Yamase H, Ergin MT, et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting- cell-based vaccine in melanoma. Cancer Immunol Immunother 1998; 47:58-64; PMID:9755879; http://dx.doi.org/10.1007/s002620050504.
29. Dobrzanski MJ, Rewers-Felkins KA, Samad KA, Quinlin IS, Phillips CA, Robinson W, et al. Immunotherapy with IL-10- and IFN-?-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother 2012; 61:839-54; PMID:22083345; http://dx.doi.org/10.1007/s00262-011-1128-x.
30. Spisek R, Bretaudeau L, Barbieux I, Meflah K, Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 2001; 50:417-27; PMID:11726136; http://dx.doi.org/10.1007/s002620100215.
31. Thurner B, Röder C, Dieckmann D, Heuer M, Kruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223:1-15; PMID:10037230; http://dx.doi.org/10.1016/S0022-1759(98)00208-7.
32. Lou Y, Wang G, Lizée G, Kim GJ, Finkelstein SE, Feng C, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 2004; 64:6783-90; PMID:15374997;http://dx.doi.org/10.1158/0008-5472.CAN-04-1621.
33. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449.
34. Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010; 115:3508-19; PMID:20190192; http://dx.doi.org/10.1182/blood-2009-09-241398.
35. Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205:1701-14; PMID:18573906; http://dx.doi.org/10.1084/jem.20071681.
36. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leadsto mutual stabilization and increased bioactivity. J Biol Chem 2008; 283:4189-99; PMID:18055460; http://dx.doi.org/10.1074/jbc.M705725200.
37. Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 2008; 28(1B):379-87; PMID:18383873.
38. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842.
39. Wright SE, Rewers-Felkins KA, Quinlin IS, Fogler WE, Phillips CA, Townsend M, et al. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest 2008; 37:215-25; PMID:18389441; http://dx.doi.org/10.1080/08820130801967874.
40. Alajez NM, Schmielau J, Alter MD, Cascio M, Finn OJ. Therapeutic potential of a tumor-specific, MHCunrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood 2005; 105:4583-9; PMID:15746083; http://dx.doi.org/10.1182/blood-2004-10-3848.
41. Wright SE, Khaznadar R, Wang Z, Quinlin IS, Rewers-Felkins KA, Phillips CA, et al. Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand J Immunol 2008; 67:24-9; PMID:18021186.
42. Quinlin IS, Burnside JS, Dombrowski KE, Phillips CA, Dolby N, Wright SE. Context of MUC1 epitope: immunogenicity. Oncol Rep 2007; 17:453-6; PMID:17203187.
43. Kornbluth J, Flomenberg N, Dupont B. Cell surface phenotype of a cloned line of human natural killer cells. J Immunol 1982; 129:2831-7; PMID:6982944.
44. von Zons P, Crowley-Nowick P, Friberg D, Bell M, Koldovsky U, Whiteside TL. Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma. Clin Diagn Lab Immunol 1997; 4:202-7; PMID:9067656.
45. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991; 142:257-65; PMID:1919029; http://dx.doi.org/10.1016/0022-1759(91)90114-U.
46. Jost LM, Kirkwood JM, Whiteside TL. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 1992; 147:153-65; PMID:1548398; http://dx.doi.org/10.1016/S0022-1759(12)80003-2.
47. Ahmed SA, Gogal RM Jr., Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H] thymidine incorporation assay. J Immunol Methods 1994; 170:211-24; PMID:8157999; http://dx.doi.org/10.1016/0022-1759(94)90396-4.
48. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID:6606682; http://dx.doi.org/10.1016/0022-1759(83)90303-4.